FDA supplemental approval: Carbamazepine (Labeling)

AI Summary

The FDA approved a supplemental labeling change for carbamazepine extended-release tablets (100 mg, 200 mg, and 400 mg) manufactured by Zydus Pharmaceuticals on 29 April 2026. This is a regulatory action document and contains no clinical trial results, efficacy data, or safety outcomes.

Plain-language summary

FDA supplemental approval of labeling changes for carbamazepine extended-release tablets; does not report clinical trial outcomes or efficacy data.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This record documents a labeling change but does not provide information to guide clinical decision-making. Clinicians should consult the updated FDA-approved product label for any changes to indications, dosing, contraindications, or safety information.

Caveats

• Record does not contain clinical trial results, efficacy data, or safety outcomes
• Specific labeling changes are not detailed in this submission record
• No information on the rationale or nature of the labeling supplement provided

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.